<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467960</url>
  </required_header>
  <id_info>
    <org_study_id>Melitta-ApoD-2011</org_study_id>
    <nct_id>NCT01467960</nct_id>
  </id_info>
  <brief_title>Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease</brief_title>
  <acronym>ApoD</acronym>
  <official_title>Detection of Apolipoprotein D (ApoD) in Human Serum as Marker of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Privatklinik Villa Melitta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Privatklinik Villa Melitta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Italy affected people are 200,000 and every year Parkinson new cases are 10,000. Aging is
      the principle risk factor of Parkinson with the possibility of its development doubling every
      five years after 65. Because of the increase of the social longevity and aging as the main
      risk factor, there are many repercussions on the health system (hospital stays and
      pharmaceutical costs) as on the social system (assistance- related problems). Parkinson's
      disease exerts an extremely negative impact on life's quality of the patient. In fact,
      because of Parkinson symptoms (tremor, dribble, etc), patient's social life will be reduced
      with the consequent development of the depression. Consequently, the early detection and
      treatment of Parkinson's is necessary.

      To achieve this goal, Apolipoprotein D (ApoD) in human serum as a marker of the oxidative
      stress-inflammation vicious cycle seems most promising candidate for diagnosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total participants: n=180.

      Study Part 1:

      Health persons: n=90; Groups of health persons: n=3; Subjects per group: n=30.

      Study Part 2:

      Patients: n=90; Groups of patients: n=3; Subjects per group: n=30.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of Apolipoprotein D</measure>
    <time_frame>Baseline</time_frame>
    <description>Apolipoprotein D (apoD)concentration in human serum as a potential marker for Parkinson's disease (PD)</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">180</enrollment>
  <condition>Parkinson's</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <description>Healthy Subjects aged 20-40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <description>Healthy Subjects aged 40-65</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <description>Healthy Subjects aged more than 65</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients at Stage I, H&amp;Y classification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients at Stage II, H&amp;Y classification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>Patients at Stage more than III, H&amp;Y classification</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All the recruited subjects will be either healthy people group or patients with a defined
        diagnosis of Parkinson (classification of Hoehn and Yahr).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Parkinson's disease in the pathological related stages (Hoehn and Yahr)

          -  Persons &gt; 20 years

        Exclusion Criteria:

          -  Patients with a neurodegenerative disorder different to Parkinson's disease

          -  Patients, who are post-ictus and/or traumatic brain injury (TBI)

          -  Patients, who are treated with antipsychotic drugs

          -  Obese persons (BMI &gt; 27)

          -  Idiopathic normal pressure idrocephalus (INPI)

          -  Paget's disease

          -  Breast cancer

          -  Adenocarcinoma of the prostate

          -  Glucose-6-phosphate (GSD-I) deficiency

          -  Insuline-resistance-related disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Waldner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Privatklinik Villa Melitta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Dassati, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Privatklinik Villa Melitta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Privatklinik Villa Melitta</name>
      <address>
        <city>Bozen</city>
        <state>SÃ¼dtirol</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <link>
    <url>http://www.villamelitta.it</url>
    <description>Participating Centre for ApoD Detection</description>
  </link>
  <link>
    <url>http://www.sbbz.it</url>
    <description>Participating Centre for ApoD Detection</description>
  </link>
  <reference>
    <citation>Bennett MD. The time and duration of meiosis. Philos Trans R Soc Lond B Biol Sci. 1977 Mar 21;277(955):201-26. Review.</citation>
    <PMID>16285</PMID>
  </reference>
  <reference>
    <citation>Patterson D, Carnright DV. Biochemical genetic analysis of pyrimidine biosynthesis in mammalian cells: I. Isolation of a mutant defective in the early steps of de novo pyrimidine synthesis. Somatic Cell Genet. 1977 Sep;3(5):483-95.</citation>
    <PMID>21463</PMID>
  </reference>
  <reference>
    <citation>Arnesen K, Nordstoga K. Ocular encephalitozoonosis (nosematosis) in blue foxes. Polyarteritis nodosa and cataract. Acta Ophthalmol (Copenh). 1977 Aug;55(4):641-51.</citation>
    <PMID>19918</PMID>
  </reference>
  <reference>
    <citation>Weidler DJ, Sieck GC. A study of ion binding in the hemolymph of Periplaneta americana. Comp Biochem Physiol A Comp Physiol. 1977;56(1A):11-4.</citation>
    <PMID>11058</PMID>
  </reference>
  <reference>
    <citation>Bergdahl B, Andersson KE. Stability in vitro of methylproscillaridin. Eur J Clin Pharmacol. 1977 Apr 20;11(4):267-71.</citation>
    <PMID>16755</PMID>
  </reference>
  <reference>
    <citation>Kovatsis A, Kovatsi-Kotsaki V, Elezoglou B, Kounenis G. Physiological antagonism between PGE2, PGA1, PGF1-alpha and NADP, beta-NAD on isolated rabbit jejunum. Arzneimittelforschung. 1976;26(11):1997-9.</citation>
    <PMID>14647</PMID>
  </reference>
  <results_reference>
    <citation>Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener. 2009 Nov 23;4:48. doi: 10.1186/1750-1326-4-48.</citation>
    <PMID>19930651</PMID>
  </results_reference>
  <results_reference>
    <citation>Dalmark M. Chloride in the human erythrocyte: distribution and transport between cellular and extracellular fluids and structural features of the cell membrane. Prog Biophys Mol Biol. 1976;31(2):145-64. Review.</citation>
    <PMID>10601</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller J, Wallace D, Grieco MH, Frenkel R, Larsen K. Double-blind trial of oral carbuterol in bronchial asthma. Ann Allergy. 1977 Jul;39(1):12-7.</citation>
    <PMID>18957</PMID>
  </results_reference>
  <results_reference>
    <citation>Fall RR. Stabilization of an acetyl-coenzyme A carboxylase complex from Pseudomonas citronellolis. Biochim Biophys Acta. 1976 Dec 20;450(3):475-80.</citation>
    <PMID>12801</PMID>
  </results_reference>
  <results_reference>
    <citation>Hong JS. An ecf mutation in Escherichia coli pleiotropically affecting energy coupling in active transport but not generation or maintenance of membrane potential. J Biol Chem. 1977 Dec 10;252(23):8582-8.</citation>
    <PMID>21876</PMID>
  </results_reference>
  <results_reference>
    <citation>Kricka LJ, Carter TJ. A method for enhancing the stability of thiol-containing enzymes immobilised on nylon. Clin Chim Acta. 1977 Aug 15;79(1):141-7.</citation>
    <PMID>19176</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <results_first_submitted>June 11, 2013</results_first_submitted>
  <results_first_submitted_qc>June 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2013</results_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Privatklinik Villa Melitta</investigator_affiliation>
    <investigator_full_name>Andreas Waldner</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>90 healthy subjects are enrolled on the base of their age being classified in the groups I (20-40), II (40-65) and three (&gt;than 65). 90 patients are enrolled on the base of their disease's stage (Hoehn and Yahr classification) being classified in the groups A (I, H&amp;Y), B (II, H&amp;Y) and C (&gt; than II, H&amp;Y).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group I</title>
          <description>30 Healthy Subjects aged 20-40</description>
        </group>
        <group group_id="P2">
          <title>Group II</title>
          <description>30 Healthy Subjects aged 40-65</description>
        </group>
        <group group_id="P3">
          <title>Group III</title>
          <description>30 Healthy Subjects aged more than 65</description>
        </group>
        <group group_id="P4">
          <title>Group A</title>
          <description>30 Patients at Stage I, H&amp;Y classification</description>
        </group>
        <group group_id="P5">
          <title>Group B</title>
          <description>30 Patients at Stage II, H&amp;Y classification</description>
        </group>
        <group group_id="P6">
          <title>Group C</title>
          <description>30 Patients at Stage more than III, H&amp;Y classification</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Enrollment of patients (PD) in 09/2013</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I</title>
          <description>Healthy Subjects aged 20-40</description>
        </group>
        <group group_id="B2">
          <title>Group II</title>
          <description>Healthy Subjects aged 40-65</description>
        </group>
        <group group_id="B3">
          <title>Group III</title>
          <description>Healthy Subjects aged more than 65</description>
        </group>
        <group group_id="B4">
          <title>Group A</title>
          <description>Patients at Stage I, H&amp;Y</description>
        </group>
        <group group_id="B5">
          <title>Group B</title>
          <description>Patients at Stage II, H&amp;Y</description>
        </group>
        <group group_id="B6">
          <title>Group C</title>
          <description>Patients at stage &gt; than II, H&amp;Y</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="30"/>
            <count group_id="B6" value="30"/>
            <count group_id="B7" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>PARTECIPANTS</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Detection of Apolipoprotein D</title>
        <description>Apolipoprotein D (apoD)concentration in human serum as a potential marker for Parkinson's disease (PD)</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I</title>
            <description>Healthy Subjects aged 20-40</description>
          </group>
          <group group_id="O2">
            <title>Group II</title>
            <description>Healthy Subjects aged 40-65</description>
          </group>
          <group group_id="O3">
            <title>Group III</title>
            <description>Healthy Subjects aged more than 65</description>
          </group>
          <group group_id="O4">
            <title>Group A</title>
            <description>Patients at Stage I, H&amp;Y</description>
          </group>
          <group group_id="O5">
            <title>Group B</title>
            <description>Patients at Stage II, H&amp;Y</description>
          </group>
          <group group_id="O6">
            <title>Group C</title>
            <description>Patients at stage &gt; than II, H&amp;Y</description>
          </group>
        </group_list>
        <measure>
          <title>Detection of Apolipoprotein D</title>
          <description>Apolipoprotein D (apoD)concentration in human serum as a potential marker for Parkinson's disease (PD)</description>
          <units>microg / ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.28" spread="4.01"/>
                    <measurement group_id="O2" value="27.73" spread="7.26"/>
                    <measurement group_id="O3" value="34.61" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events weren not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Group I</title>
          <description>Healthy Subjects aged 20-40</description>
        </group>
        <group group_id="E2">
          <title>Group II</title>
          <description>Healthy Subjects aged 40-65</description>
        </group>
        <group group_id="E3">
          <title>Group III</title>
          <description>Healthy Subjects aged more than 65</description>
        </group>
        <group group_id="E4">
          <title>Group A</title>
          <description>Patients at Stage I, H&amp;Y</description>
        </group>
        <group group_id="E5">
          <title>Group B</title>
          <description>Patients at Stage II, H&amp;Y</description>
        </group>
        <group group_id="E6">
          <title>Group C</title>
          <description>Patients at stage &gt; than II, H&amp;Y</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sarah Dassati</name_or_title>
      <organization>Villa Melitta</organization>
      <phone>+39 0471 471 ext 471</phone>
      <email>sarahdassati@yahoo.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

